Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TELA Bio (TELA) Accumulated Expenses (2018 - 2025)

TELA Bio has reported Accumulated Expenses over the past 8 years, most recently at $15.7 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $15.7 million for Q4 2025, up 113.35% from a year ago — trailing twelve months through Dec 2025 was $15.7 million (up 113.35% YoY), and the annual figure for FY2025 was $15.7 million, up 113.35%.
  • Accumulated Expenses for Q4 2025 was $15.7 million at TELA Bio, up from $6.8 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for TELA hit a ceiling of $15.7 million in Q4 2025 and a floor of $3.4 million in Q2 2021.
  • Median Accumulated Expenses over the past 5 years was $7.2 million (2021), compared with a mean of $8.6 million.
  • Biggest five-year swings in Accumulated Expenses: soared 20302.5% in 2021 and later tumbled 52.99% in 2025.
  • TELA Bio's Accumulated Expenses stood at $8.2 million in 2021, then fell by 21.33% to $6.4 million in 2022, then soared by 43.55% to $9.2 million in 2023, then fell by 20.32% to $7.3 million in 2024, then soared by 113.35% to $15.7 million in 2025.
  • The last three reported values for Accumulated Expenses were $15.7 million (Q4 2025), $6.8 million (Q3 2025), and $14.0 million (Q2 2025) per Business Quant data.